Forward looking statements about Cyclacel Pharmaceuticals, Inc. - Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc. 00:00:00
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced solid cancers and in combination with venetoclax in patients with advanced hematological malignancies.